JAK1/JAK2 inhibitors, such as INCB039110 [318] or ruxolitinib (INCB18424), are currently in clinical phase I and II trials in B-cell lymphoma, including relapsed/refractory DLBCL (NCT01905813, NCT01431209), or have been suggested for further clinical evaluation in DLBCL (pacritinib, SB1518), including relapsed or refractory DLBCL [109, 317, 318] (Additional file 1: Table S6). This evidence concerns the gene JAK2 and diffuse large B-cell lymphoma.